Goodwill and Intangible Assets - Additional Information (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Jan. 01, 2025 |
|
| Goodwill [Line Items] | ||||||
| Amortization expense | $ 716,000 | $ 773,000 | $ 1,431,000 | $ 1,547,000 | ||
| Patient services | ||||||
| Goodwill [Line Items] | ||||||
| Goodwill impairment charges | 26,179,000 | 26,179,000 | $ 26,179,000 | $ 26,179,000 | ||
| Clinical trials & other | ||||||
| Goodwill [Line Items] | ||||||
| Goodwill impairment charges | 632,000 | 632,000 | 632,000 | |||
| Specialty pharmacy | ||||||
| Goodwill [Line Items] | ||||||
| Goodwill impairment charges | $ 0 | $ 0 | $ 0 | $ 0 | ||
| X | ||||||||||
- Definition Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|